Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.
Laura ThümmlerMonika LindemannPeter A HornVeronika LenzMargarethe KonikAnja GäcklerKristina BossFotis TheodoropoulosVasiliki BesaChristian TaubeThorsten BrennerOliver WitzkeAdalbert KrawczykHana RohnPublished in: Viruses (2022)
Vulnerable patients such as immunosuppressed or elderly patients are at high risk for a severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with SARS-CoV-2 specific monoclonal antibodies (mAb) or convalescent plasma represents a considerable treatment option to protect these patients from a severe or lethal course of infection. However, monoclonal antibodies are not always available or less effective against emerging SARS-CoV-2 variants. Convalescent plasma is more commonly available and may represent a good treatment alternative in low-income countries. We retrospectively evaluated outcomes in individuals treated with mAbs or convalescent plasma and compared the 30-day overall survival with a patient cohort that received supportive care due to a lack of SARS-CoV-2 specific therapies between March 2020 and April 2021. Our data demonstrate that mAb treatment is highly effective in preventing severe courses of SARS-CoV-2 infection. All patients treated with mAb survived. Treatment with convalescent plasma improved overall survival to 82% compared with 61% in patients without SARS-CoV-2 targeted therapy. Our data indicate that early convalescent plasma treatment may be an option to improve the overall survival of high-risk COVID-19 patients. This is especially true when other antiviral drugs are not available or their efficacy is significantly reduced, which may be the case with emerging SARS-CoV-2 variants.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- ejection fraction
- newly diagnosed
- prognostic factors
- coronavirus disease
- type diabetes
- cardiovascular disease
- palliative care
- gene expression
- machine learning
- chronic pain
- metabolic syndrome
- risk factors
- patient reported outcomes
- weight loss
- quality improvement
- smoking cessation
- replacement therapy
- drug induced
- health insurance
- patient reported
- data analysis
- affordable care act